Subscribe To

Price Alert Latest News Economic Calendar News

EMMA / Emmaus Life Sciences says Q3 revenue boosted by sales of Endari in the United Arab Emirates

Emmaus Life Sciences Inc (OTCQX:EMMA) has reported net revenue of $4.9 million for the third quarter of 2022, nearly 15% higher than the $4.3 million recorded in the second quarter, boosted primarily by its sickle cell oral therapy Endari in the United Arab Emirates after it was approved for sale in May this year. "We enjoyed a third straight substantial increase in quarterly net revenue due to increased sales in the Middle East North Africa region. Read More

Demo Live Account See Partner Details

Content Topics

Emmaus

Life

Sciences

Says

Revenue

Boosted

Sales

Endari

United

Emirates

Stock

EMMA

Posted: Nov 15 2022, 08:02

Author Name: Proactive Investors

EMMA News

By Proactive Investors
August 23, 2023

Emmaus Life Sciences to focus on boosting sales of its sickle cell disease treatment Endari amid leadership transition

Emmaus Life Sciences Inc (OTCQX:EMMA) said its Dr. Yutaka Niihara will no longer serve as the company's CEO as Dr.

By Proactive Investors
August 14, 2023

Emmaus Life Sciences 2Q revenue surges as MENA sales climb

Emmaus Life Sciences Inc (OTCQX:EMMA) has announced record second-quarter 2023 net revenues of $10.8 million, up from $4.3 million a year earlier an

By Proactive Investors
July 13, 2023

Emmaus Life Sciences receives approval to market Endari in Oman

Emmaus Life Sciences Inc (OTCQX:EMMA) announced that it has received marketing authorization from the Ministry of Health in Oman for the commercial di

By Proactive Investors
May 31, 2023

Emmaus Life Sciences receives approval to market Endari in Bahrain

Emmaus Life Sciences Inc (OTCQX:EMMA) announced that it has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Heal

By Proactive Investors
May 15, 2023

Emmaus Life Sciences sees 1Q revenue surge 109% on boost in US and MENA sales

Emmaus Life Sciences Inc (OTCQX:EMMA) has announced that its first-quarter 2023 net revenues rose 109% year over year to $6.8 million, which the com

By Proactive Investors
April 3, 2023

Emmaus Life Sciences sees ‘strong' sales momentum for coming year

Emmaus Life Sciences Inc (OTCQX:EMMA) has said sales momentum is “strong” for the coming year as it reported results the 12 months ended December

By Proactive Investors
December 19, 2022

Emmaus Life Sciences CEO Dr Yutaka Niihara highly praised by the Indian government for developing Endari

Emmaus Life Sciences Inc (OTCQX:EMMA) revealed that the company's CEO Dr Yutaka Niihara was feted at an event held on December 16, 2022, at the World

By Proactive Investors
December 7, 2022

Emmaus Life Sciences gets marketing authorization from Kuwaiti authorities for Endari

Emmaus Life Sciences Inc (OTCQX:EMMA) announced that the Kuwaiti Ministry of Health has granted marketing authorization for the commercial distributio

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.